Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in pregnancies at high risk for severe hemolytic disease of the fetus and newborn
ISRCTN12057804Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Erythroblastosis fetalis (HDFN) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Pregnancies without severe HDFN outcome. Started Dec 2023; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on ISRCTN12057804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12057804.